Immune checkpoint inhibitor rechallenge after pazopanib treatment in primary pulmonary angiosarcoma: A case report
{{output}}
Primary pulmonary angiosarcoma is a rare malignancy with limited therapeutic options. We report a case of primary pulmonary angiosarcoma in which tumor regression was achieved with immune checkpoint inhibitor (ICI) rechallenge following pazopanib therapy. The ... ...
